Material Information- Announcement of the Board’s Resolution to release the non-competition restriction on managerial officers
1.Date of the board of directors resolution:2026/08/06
2.Name and title of the managerial officer with permission to engage in competitive conduct:
(1)KC Sung/ Chief Technology Officer
(2)Qiao Li/ Chief Operating Officer of the subsidiary
3.Items of competitive conduct in which the officer is permitted to engage:
(1)KC Sung: Executive Director and Manager of Hangzhou Hanlux Pharmaceutical Technology Co.,Ltd.
(2)Qiao Li: Legal Representative of Hangzhou Hanlux Pharmaceutical Technology Co.,Ltd.
4.Period of permission to engage in the competitive conduct:During the tenure as a managerial officer of the Company
5.Circumstances of the resolution (please describe the results of voting in accordance with Article 32 of the Company Act):This proposal is approved by all of the Directors presented at the meeting.
6.If the permitted competitive conduct belongs to the operator of a mainland China enterprise, the name and title of the managerial officer (if it is not the operator of a mainland China enterprise, please enter“N/A” below):
(1)KC Sung/ Chief Technology Officer
(2)Qiao Li/ Chief Operating Officer of the subsidiary
7.Company name of the mainland China enterprise and the officer’s position in the enterprise:
(1)KC Sung: Executive Director and Manager of Hangzhou Hanlux Pharmaceutical Technology Co.,Ltd.
(2)Qiao Li: Legal Representative of Hangzhou Hanlux Pharmaceutical Technology Co.,Ltd.
8.Address of the mainland China enterprise:Room 605, Building 2, No. 99 Xiangyuan Road, Gongshu District, Hangzhou, Zhejiang, China
9.Operations of the mainland China enterprise:Technical services; technology development; technical consulting; technical collaboration; and technology promotion; medical research and experimental development (excluding the development and application of human stem cell, gene diagnosis, and gene therapy technologies); import and export of goods. (Except for projects requiring approval in accordance with applicable laws and regulations, business activities shall be conducted independently based on the business license.)
10.Impact on the company’s finance and business:None
11.If the managerial officer or director has invested in the mainland China enterprise, the monetary amount of the investment and the officer or director’s shareholding ratio:NA
12.Any other matters that need to be specified:None